Alexis LeVee, MD

Alexis LeVee, MD, is chief Hematology & Medical Oncology fellow at City of Hope

Articles

HER2-Negative and HER2-Low mBC: Key Takeaways

July 28th 2025

Panelists discuss how the field has made exciting strides, with oral selective estrogen receptor degraders (SERDs) likely moving into early-stage disease and the need for alternative antibody-drug conjugate (ADC) payloads beyond topoisomerase I inhibitors to overcome resistance mechanisms.

Defining HER2-Low and -Ultralow Expression: Practical Challenges and Solutions

July 28th 2025

Panelists discuss how HER2 testing challenges for identifying HER2-low and -ultralow expression require coordination with pathologists and may involve

Sequencing ADCs in HER2-Low and -Ultralow mBC: Clinical Considerations and Emerging Evidence

July 21st 2025

Panelists discuss how they approach sequencing decisions for patients with hormone receptor–positive, HER2- low/ultralow disease, emphasizing selective use of trastuzumab deruxtecan in first-line chemotherapy settings while considering quality-of-life factors.

DESTINY-Breast06: Updates From Subgroup and Biomarker Analyses

July 21st 2025

Panelists discuss how subgroup analyses from DESTINY-Breast06 show trastuzumab deruxtecan benefits across different mutation groups, with particularly strong responses in patients with BRCA1/2-mutated disease due to the topoisomerase I inhibitor payload.

Navigating Treatment Selection for HER2-Low and -Ultralow Metastatic Breast Cancer

July 14th 2025

Panelists discuss how treatment options for HER2-low and HER2-ultralow metastatic breast cancer include trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, with sequencing becoming a key consideration.

Balancing Efficacy and Safety of ADCs in HER2– Metastatic Breast Cancer

July 14th 2025

Panelists discuss how to manage toxicities associated with datopotamab deruxtecan, particularly ocular toxicity and stomatitis, using prophylactic measures such as steroid mouthwash and eye drops.

Evolving ADC Strategies in HER2– mBC: TROPION-Breast01 and Real-World Data From ASCO 2025

July 7th 2025

Panelists discuss how datopotamab deruxtecan from the TROPHY-PD-01 trial compares with sacituzumab govitecan, highlighting different toxicity profiles and the challenge of sequencing multiple antibody-drug conjugates (ADCs) with the same TROP2 payload.

TROPiCS-02 Trial: Sacituzumab Govitecan in HR+/HER2– Breast Cancer

July 7th 2025

Panelists discuss how the TROPiCS-02 trial established sacituzumab govitecan for hormone receptor–positive, HER2-negative metastatic breast cancer and how it influences sequencing decisions with other antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan.

When to Introduce ADCs in HR+/HER2– mBC

June 30th 2025

Panelists discuss how they decide when to transition from endocrine-based therapies to antibody-drug conjugates, considering factors such as endocrine sensitivity, disease burden, and pace of progression.

Optimizing Treatment Selection and Sequencing in HR+/HER2– mBC

June 30th 2025

Panelists discuss how to approach decision-making among PI3K/AKT pathway inhibitors (capivasertib, alpelisib, everolimus) based on mutation status, toxicity profiles, and dosing schedules in the second-line setting.

Efficacy and Safety of Next-Generation Oral SERDs for HR+/HER2– mBC

June 23rd 2025

Panelists discuss how upcoming oral selective estrogen receptor degraders (SERDs; eg, camasertinib, imlunestrant, and giredestrant) are showing efficacy primarily in populations with ESR1 mutations and are all well-tolerated oral agents that will likely receive approvals.

The Role of Elacestrant in the Treatment of ER+/HER2– mBC

June 23rd 2025

Panelists discuss how elacestrant from the EMERALD trial is being incorporated into practice based on ESR1 mutation status and duration of prior CDK4/6 inhibitor therapy, with combination approaches being explored in the ELEVATE trial.

Camizestrant in HR+/HER2– mBC: Emerging Data From the SERENA-6 Trial

June 16th 2025

Panelists discuss how the SERENA-6 trial design uses circulating tumor DNA (ctDNA) monitoring to detect ESR1 mutations and switch patients from aromatase inhibitors to oral selective estrogen receptor degraders (SERDs) such as camasertinib while continuing CDK4/6 inhibitors.

Biomarker Testing Strategies in Metastatic Breast Cancer

June 16th 2025

Panelists discuss how they will review the latest updates in hormone receptor–positive, HER2-negative, and HER2-low metastatic breast cancer, focusing on oral selective estrogen receptor degraders (SERDs), targeted therapies, and antibody-drug conjugates presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr LeVee on ADC Trials That May Inform the Evolution of Breast Cancer Management

May 19th 2025

Alexis LeVee, MD, discusses clinical trials investigating ADCs that may change treatment standards for patients with various subtypes of breast cancer.

Dr LeVee on Ongoing Research With Immunotherapy and ADCs in TNBC

May 15th 2025

Alexis LeVee, MD, discusses ongoing trials investigating immunotherapy agents and antibody-drug conjugates that may challenge the current SOC for TNBC.

Dr LeVee on Immune-Related AEs Associated With ICIs in Early Breast Cancer

January 6th 2025

Alexis LeVee, MD, discusses immune-related adverse effects in patients with early breast cancer treated with immune checkpoint inhibitors.

x